Rivoceranib
Small molecule targets KDR, KIT, RET, SRC via inhibition
Trials 531 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04074564 | Nov 2019 → Aug 2024 | sarcoma | HRYZ Biotech Co. | Unknown | No outcome recorded |
| Phase 133 trials | ||||||
| Phase 1 | NCT06769425 | May 2025 → May 2026 overdue | female breast carcinoma, gastric cancer, ovarian cancer, prostate cancer +1 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06181032 | Dec 2023 → Feb 2029 expected | biliary tract cancer | First Affiliated Hospital of Fujian Medical University | Recruiting | No outcome recorded |
| Phase 1 | NCT05287360 | Dec 2021 → Mar 2022 | — | Elevar Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05001412 | Jan 2021 → Jan 2023 | small cell lung carcinoma | Zhou Chengzhi | Unknown | No outcome recorded |
| Phase 1 | NCT04665362 | Jan 2021 → Jun 2022 | hepatocellular carcinoma | Liang Peng | Unknown | No outcome recorded |
| Phase 1 | NCT04457180 | Nov 2020 → May 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04428086 | Jul 2020 → Aug 2021 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04414852 | Jun 2020 → Jan 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04390984 | May 2020 → Feb 2021 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04341090 | May → Jul 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04393506 | Apr → Nov 2020 | oral cavity cancer | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT04322552 | Mar 2020 → Apr 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04073615 | Nov 2019 → May 2023 | colorectal cancer | Elevar Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT03645200 | Jul → Dec 2019 | cancer of unknown primary site | Tianjin Medical University Second Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT04073784 | Jun 2019 → Apr 2022 | nasopharyngeal carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 1 | NCT03945604 | Jun 2019 → Feb 2021 | triple-negative breast carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03491631 | Nov 2018 → Jun 2023 | metastatic malignant neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03407976 | Jun 2018 → Aug 2019 | adenocarcinoma, urothelial carcinoma | University of Utah | Terminated | No outcome recorded |
| Phase 1 | NCT03244774 | Jan → Dec 2018 | gastric adenocarcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03396211 | Dec 2017 → Oct 2020 | cancer | Elevar Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03245307 | Aug 2017 → Apr 2018 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03243643 | Aug 2017 → Jul 2019 | cancer of unknown primary site | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03075462 | Mar 2017 → Aug 2021 | ovarian cancer, triple-negative breast carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03026881 | Jan 2017 → Apr 2018 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02836171 | Jul 2016 → Feb 2017 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02836821 | May 2016 → Feb 2017 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03050411 | May 2016 → Jun 2019 | non-small cell lung carcinoma | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT02711969 | Mar → Nov 2016 | gastric cancer | Bukwang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03276156 | Feb 2016 → Feb 2018 | gastric cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT02691871 | Feb → Oct 2016 | lung adenocarcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 1 | NCT02645864 | Jan 2016 → Dec 2018 | esophageal squamous cell carcinoma | Peking University | Completed | No outcome recorded |
| Phase 1 | NCT03071042 | Oct 2015 → Dec 2017 | gastric adenocarcinoma | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT00633490 | Jul 2007 → Jun 2008 | neoplasm | Fudan University | Unknown | No outcome recorded |
| Phase 1/231 trials | ||||||
| Phase 1/2 | NCT07479732 | Mar 2026 → Mar 2027 expected | osteosarcoma | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06592287 | Sep 2024 → Sep 2025 overdue | gastric cancer | Xianglin Yuan | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06607770 | Sep 2024 → Aug 2026 overdue | lung cancer | Zhou Chengzhi | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05924997 | Jul 2023 → Jun 2025 | hepatocellular carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05742750 | Apr 2023 → Dec 2025 | biliary tract cancer | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 1/2 | NCT05559008 | Sep 2022 → Mar 2024 | peripheral T-cell lymphoma, not otherwise specified | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT05019690 | Oct 2021 → Dec 2024 overdue | triple-negative breast carcinoma | Fujian Cancer Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05027386 | Aug 2021 → Feb 2026 overdue | neuroblastoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04476459 | Jul 2020 → Aug 2022 | ALK-positive anaplastic large cell lymphoma, high grade B-cell lymphoma | Huiqiang Huang | Unknown | No outcome recorded |
| Phase 1/2 | NCT04446091 | Jul 2020 → Jul 2021 | colorectal cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04659785 | Jul 2020 → Jul 2021 | small cell lung carcinoma | Tianjin Medical University Second Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04202978 | Mar 2020 → Mar 2021 | metastasis from malignant tumor of colon | Zhongshan Hospital Xiamen University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04286711 | Mar → Aug 2020 | gastric cancer | China Medical University, China | Unknown | No outcome recorded |
| Phase 1/2 | NCT04572542 | Jan 2020 → Jun 2021 | gastroesophageal adenocarcinoma | The First Affiliated Hospital of Xiamen University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04201990 | Dec 2019 → Dec 2021 | lung cancer | ShiYue Li | Unknown | No outcome recorded |
| Phase 1/2 | NCT04182724 | Nov 2019 → May 2021 | gastric cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04133337 | Nov 2019 → Jun 2020 | non-small cell lung carcinoma | Sichuan Cancer Hospital and Research Institute | Unknown | No outcome recorded |
| Phase 1/2 | NCT04067986 | Aug 2019 → Sep 2020 | colorectal cancer | Zhongshan Hospital Xiamen University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04035876 | Jul 2019 → Dec 2021 | hepatocellular carcinoma | Zhejiang University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03868852 | Jan 2019 → Apr 2020 | rhabdomyosarcoma | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 1/2 | NCT03805399 | Oct 2018 → Dec 2022 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03654612 | Oct 2018 → Mar 2020 | head and neck cancer | China International Medical Foundation | Unknown | No outcome recorded |
| Phase 1/2 | NCT03707028 | Oct 2018 → Aug 2021 | gastric cancer, gastroesophageal junction adenocarcinoma | Elevar Therapeutics | Terminated | No outcome recorded |
| Phase 1/2 | NCT03599778 | Sep 2018 → Jan 2025 | gastric carcinoma | Anhui Provincial Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT03201146 | Jun 2017 → Jul 2020 | non-small cell lung carcinoma | West China Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT02942329 | Oct 2016 → Oct 2018 | gastric cancer, hepatocellular carcinoma | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT02848794 | Jul 2016 → Jul 2018 | malignant glioma | The First People's Hospital of Lianyungang | Unknown | No outcome recorded |
| Phase 1/2 | NCT02844881 | Jul 2016 → Jul 2018 | T-cell non-Hodgkin lymphoma, cancer | The First People's Hospital of Lianyungang | Unknown | No outcome recorded |
| Phase 1/2 | NCT02772029 | May 2016 → Sep 2017 | hepatocellular carcinoma | The First Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02727309 | Oct 2015 → Dec 2018 | hepatocellular carcinoma | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| Phase 1/2 | NCT01497704 | Apr 2012 → Feb 2015 | — | Elevar Therapeutics | Completed | No outcome recorded |
| Phase 2368 trials | ||||||
| Phase 2 | NCT07684040 | Aug 2026 → Jul 2030 expected | liver cancer | Affiliated Hospital of Guangdong Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07687433 | May 2026 → May 2028 expected | rectal cancer | Harbin Medical University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07610629 | May 2026 → Dec 2028 expected | gastric adenocarcinoma | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07464756 | Apr 2026 → May 2028 expected | gastric adenocarcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT07463248 | Mar 2026 → Jan 2028 expected | hepatocellular carcinoma | Wang Xin | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07333287 | Feb 2026 → Feb 2027 expected | digestive system carcinoma | Shandong Provincial Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07314372 | Feb 2026 → Dec 2027 expected | adult hepatocellular carcinoma | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07357532 | Jan 2026 → Sep 2028 expected | small cell lung carcinoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07363356 | Jan → Oct 2026 expected | hepatocellular carcinoma | Eastern Hepatobiliary Surgery Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07324473 | Jan 2026 → Jan 2028 expected | hepatocellular carcinoma | First Affiliated Hospital of Chongqing Medical University | Not yet recruiting | No outcome recorded |
| Show all 368 trials opens the full record — a long page | ||||||
| Phase 2/318 trials | ||||||
| Phase 2/3 | NCT07653451 | Jul 2026 → Dec 2027 expected | esophageal squamous cell carcinoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07589244 | May 2026 → Dec 2028 expected | hepatocellular carcinoma | Guangzhou Virotech Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06739317 | Jan 2025 → Dec 2030 expected | hepatocellular carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05699655 | May 2023 → Mar 2025 overdue | — | Fujian Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04968002 | Aug 2021 → Aug 2022 | non-small cell lung carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05062837 | Jun 2021 → Sep 2024 | hepatocellular carcinoma | Guangxi Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04803539 | Apr 2021 → Sep 2028 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04521153 | Mar 2021 → Jul 2025 overdue | hepatocellular carcinoma | Shanghai Zhongshan Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04208347 | Dec 2019 → Dec 2026 expected | gastroesophageal adenocarcinoma | Ruijin Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03580395 | Jun 2017 → Jul 2022 | breast cancer | Hebei Medical University Fourth Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03285906 | Mar 2017 → Jun 2019 | Barrett esophagus, esophageal cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02780778 | May 2016 → Dec 2017 | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02711007 | Mar 2016 → Dec 2017 | metastatic neoplasm, osteosarcoma | GUO WEI | Completed | No outcome recorded |
| Phase 2/3 | NCT02702323 | Mar 2016 → Mar 2018 | hepatocellular carcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02509806 | Jul 2015 → Dec 2017 | gastric cancer | Hebei Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02510469 | Jul 2015 → Jul 2018 | gastric cancer | Hebei Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02409199 | Jun 2015 → Dec 2016 | gastric carcinoma | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT00970138 | Jun 2009 → Oct 2010 | gastric carcinoma | Fudan University | Completed | No outcome recorded |
| Phase 343 trials | ||||||
| Phase 3 | NCT07314203 | Dec 2026 → Aug 2027 expected | gastric cancer | Fujian Medical University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06925243 | Apr 2025 → Dec 2027 expected | gastroesophageal adenocarcinoma | Zuoyi Jiao | Recruiting | No outcome recorded |
| Phase 3 | NCT06913777 | Apr 2025 → Oct 2026 expected | — | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT06889688 | Feb 2025 → Dec 2028 expected | triple-negative breast carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT06188455 | Dec 2024 → Dec 2025 overdue | ovarian cancer | The First Affiliated Hospital of Xiamen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06539091 | Oct 2024 → Oct 2025 overdue | malignant epithelial tumor of ovary | Anhui Provincial Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06255392 | Jun 2024 → Mar 2031 expected | Her2-receptor negative breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT07371910 | Jun 2024 → Mar 2031 expected | Her2-receptor negative breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06438627 | May 2024 → May 2026 overdue | nasopharyngeal carcinoma | XIANG YANQUN | Recruiting | No outcome recorded |
| Phase 3 | NCT06447623 | Feb 2024 → Feb 2027 expected | hormone receptor-positive breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT06172205 | Jul 2023 → Jul 2028 expected | chemotherapy-induced toxicity, hepatocellular carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05889871 | Jun 2023 → Jun 2026 | hormone receptor-positive breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 3 | NCT05854849 | May 2023 → Dec 2025 overdue | nasopharyngeal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05320692 | Aug 2022 → Jul 2026 overdue | hepatocellular carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05313282 | Jun 2022 → Nov 2024 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT05198609 | Jan 2022 → Jul 2026 overdue | hepatocellular carcinoma | Sun Yat-sen University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05049681 | Dec 2021 → Dec 2022 | esophageal cancer | Feng Wang | Unknown | No outcome recorded |
| Phase 3 | NCT04639180 | Apr 2021 → Jul 2026 overdue | hepatocellular carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04342910 | Sep 2020 → Apr 2026 overdue | gastric cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT04490421 | Aug 2020 → Aug 2021 | small cell lung carcinoma | Fuzhou General Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04335006 | Jul 2020 → Apr 2023 | triple-negative breast carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT04296370 | Jul 2020 → Jun 2022 | Her2-receptor negative breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04203485 | Jun 2020 → Mar 2022 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04229615 | Jun 2020 → Jun 2023 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04000295 | Aug 2019 → Jan 2021 | ovarian cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03764293 | Jun 2019 → Feb 2022 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03986385 | Jun 2019 → Jun 2020 | gastroesophageal junction adenocarcinoma | Hebei Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT03889626 | Mar 2019 → Mar 2022 | gastric cancer | Fudan University | Unknown | No outcome recorded |
| Phase 3 | NCT03813784 | Mar 2019 → Jun 2023 | gastric cancer, gastroesophageal cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03651219 | Sep 2018 → Aug 2019 | small cell lung carcinoma | Beijing Chest Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03365765 | Feb 2018 → Dec 2022 | — | Huashan Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03598348 | Jan 2018 → Jan 2020 | gastric cancer | Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 3 | NCT03355612 | Dec 2017 → Dec 2020 | gastric carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03428022 | Dec 2017 → Dec 2020 | non-small cell lung carcinoma | Shenzhen People's Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03042611 | Mar 2017 → Feb 2019 | gastric adenocarcinoma | Elevar Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT03100955 | Mar 2017 → Feb 2019 | — | Qingdao University | Unknown | No outcome recorded |
| Phase 3 | NCT03048877 | Dec 2016 → Mar 2020 | differentiated thyroid carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02875457 | Sep 2016 → Sep 2018 | small cell lung carcinoma | Third Military Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT02824458 | Jun 2016 → Dec 2023 | — | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT02332512 | Jan 2015 → Aug 2017 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT02329860 | Mar 2014 → Dec 2017 | hepatocellular carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01287962 | Apr 2011 → Apr 2013 | non-small cell lung carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT01512745 | Jan 2011 → May 2013 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 49 trials | ||||||
| Phase 4 | NCT05029453 | Aug 2021 → Dec 2022 | gastric cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 4 | NCT03792503 | Feb 2019 → Feb 2020 | non-small cell lung carcinoma | Xinqiao Hospital of Chongqing | Withdrawn | No outcome recorded |
| Phase 4 | NCT03725423 | Oct 2018 → Jun 2019 | squamous cell lung carcinoma | Xuzhou Central Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03631862 | Sep 2018 → Dec 2019 | peripheral T-cell lymphoma, not otherwise specified | Zhengzhou University | Unknown | No outcome recorded |
| Phase 4 | NCT03475589 | Feb 2018 → Dec 2020 | — | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 4 | NCT03376958 | Jan 2017 → Feb 2019 | diffuse large B-cell lymphoma | Zhengzhou University | Completed | No outcome recorded |
| Phase 4 | NCT03384511 | Sep 2016 → Jan 2018 | breast cancer, cervical cancer, esophageal cancer, gastric cancer +2 | Shandong Cancer Hospital and Institute | Completed | No outcome recorded |
| Phase 4 | NCT02776527 | Apr 2016 → Apr 2017 | gastric cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02426034 | May 2015 → May 2020 | gastroesophageal adenocarcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable28 trials | ||||||
| — | NCT07618546 | May 2026 → Mar 2027 expected | hepatocellular carcinoma | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07371871 | Jan 2026 → Dec 2027 expected | gastric cancer | Anhui Provincial Cancer Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06893887 | May 2025 → Mar 2027 expected | hepatocellular carcinoma | Nanjing Tianyinshan Hospital | Recruiting | No outcome recorded |
| — | NCT06480864 | Aug 2024 → Aug 2025 overdue | small cell lung carcinoma | Yunpeng Liu | Recruiting | No outcome recorded |
| — | NCT06102707 | Nov 2023 → Nov 2025 overdue | ovarian carcinoma | Qilu Hospital of Shandong University | Not yet recruiting | No outcome recorded |
| — | NCT05751733 | Feb 2023 → Jan 2026 overdue | gastrointestinal stromal tumor | Xiangya Hospital of Central South University | Recruiting | No outcome recorded |
| — | NCT05653817 | Jan 2023 → Jan 2025 | cholangiocarcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| — | NCT05380986 | May 2022 → May 2024 | cancer | Henan Cancer Hospital | Unknown | No outcome recorded |
| — | NCT04950400 | Jul 2021 → Dec 2023 | non-small cell lung carcinoma | Beijing Chest Hospital | Unknown | No outcome recorded |
| — | NCT04690231 | Dec 2020 → Mar 2021 | poisoning | Peking University People's Hospital | Completed | No outcome recorded |
| — | NCT03743428 | Oct 2020 → Dec 2025 | colorectal neoplasm | Shenzhen People's Hospital | Suspended | No outcome recorded |
| — | NCT04559607 | Sep 2020 → Aug 2024 | hepatocellular carcinoma | Zhongda Hospital | Unknown | No outcome recorded |
| — | NCT04501705 | Aug 2020 → Aug 2025 overdue | meningioma | Beijing Sanbo Brain Hospital | Recruiting | No outcome recorded |
| — | NCT04507750 | Aug 2020 → Aug 2021 | — | Qianfoshan Hospital | Unknown | No outcome recorded |
| — | NCT04366128 | Apr 2020 → Dec 2021 | extranodal nasal NK/T cell lymphoma | Rong Tao | Unknown | No outcome recorded |
| — | NCT03228043 | Mar 2020 → Mar 2021 | colorectal cancer | Nanchong Central Hospital | Withdrawn | No outcome recorded |
| — | NCT04174339 | Dec 2019 → Dec 2020 | gastric adenocarcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| — | NCT04260113 | Oct 2019 → Jan 2020 | poisoning | Peking University People's Hospital | Completed | No outcome recorded |
| — | NCT03722875 | Dec 2018 → Mar 2019 | hepatocellular carcinoma | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| — | NCT03671265 | Sep 2018 → Sep 2019 | esophageal cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| — | NCT03634059 | Aug 2018 → Aug 2019 | non-small cell lung carcinoma | Hebei Medical University Fourth Hospital | Unknown | No outcome recorded |
| — | NCT03349827 | Jan 2018 → Mar 2020 | peritoneal carcinomatosis | Wuhan University | Terminated | No outcome recorded |
| — | NCT03398122 | Nov 2017 → Oct 2018 | hepatocellular carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| — | NCT03255811 | Mar 2017 → Jan 2019 | gastric cancer | DongMa | Unknown | No outcome recorded |
| — | NCT03029013 | Jan 2017 → Dec 2019 | cervical cancer | Third Military Medical University | Unknown | No outcome recorded |
| — | NCT02764268 | Nov 2016 → Dec 2018 | gastric cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| — | NCT02998242 | May 2016 → Jan 2017 | — | Sichuan Provincial People's Hospital | Completed | No outcome recorded |
| — | NCT03491371 | Jun 2015 → Dec 2016 | poisoning | Peking University People's Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 24 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04581473 Comparator | Oct 2020 → Oct 2024 overdue | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, malignant pancreatic neoplasm | CARsgen Therapeutics Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT07691645 Background | Sep 2026 → Aug 2029 expected | hepatocellular carcinoma | Xiang-Qian | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07682272 Background | Jul 2026 → Jul 2027 expected | hepatocellular carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06339281 Comparator | May 2024 → Jun 2026 overdue | breast cancer | Li Huiping | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05673824 Background | Jan 2023 → Sep 2025 | poisoning | Fudan University | Completed | No outcome recorded |
| Phase 2 | NCT04683198 Background | Apr 2021 → Oct 2023 | small cell lung carcinoma | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT04383977 Comparator | May → Dec 2020 | ovarian cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04135690 Background | Oct 2019 → Dec 2023 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT04126811 Comparator | Jun → Dec 2019 | soft tissue sarcoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03520257 Background | May → Dec 2018 | hepatocellular carcinoma | Guangxi Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT02493582 Background | Jul 2015 → Jul 2030 expected | lung adenocarcinoma | The First People's Hospital of Changzhou | Active not recruiting | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07309419 Comparator | Dec 2025 → Jun 2030 expected | hepatocellular carcinoma | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06796803 Background | Feb 2025 → Feb 2028 expected | hepatocellular carcinoma | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT07267806 Background | Oct 2025 → Oct 2029 expected | chemotherapy-induced toxicity, hepatocellular carcinoma | Linhui Peng | Recruiting | No outcome recorded |
| Phase 3 | NCT06485466 Background | Aug 2024 → Jun 2026 overdue | hepatocellular carcinoma | Guohui Xu | Recruiting | No outcome recorded |
| Phase 3 | NCT06351020 Comparator | Jun 2024 → Nov 2026 expected | gastric adenocarcinoma | LaNova Medicines Zhejiang Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06346392 Comparator | Mar 2024 → May 2026 overdue | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05789043 Comparator | Mar 2023 → Aug 2026 overdue | cutaneous melanoma | Peking University Cancer Hospital & Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT05613478 Comparator | Jan 2023 → Nov 2025 overdue | hepatocellular carcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT04985136 Comparator | Sep → Dec 2021 | hepatocellular carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT04714190 Comparator | Mar 2021 → Dec 2024 | gastric cancer | RemeGen Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT02537171 Comparator | Jul 2015 → Aug 2016 | gastric cancer | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07330271 Comparator | Dec 2025 → Nov 2029 expected | peritoneal mesothelioma | Beijing Tsinghua Chang Gung Hospital | Recruiting | No outcome recorded |
| — | NCT07000344 Background | Jul 2025 → Mar 2026 | ovarian cancer | Peking Union Medical College Hospital | Terminated | No outcome recorded |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 559 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rivoceranib | “A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in...” PMID 36797744 ↗ Feb 202317“Apatinib \[Aitan® (brand name in China)\], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine...” NCT04878107 ↗ “Apatinib [Aitan® (brand name in China)], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine...” PMID 29663291 ↗ May 2018 |
| Known as | Aitan | “Apatinib \[Aitan® (brand name in China)\], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine...” NCT04878107 ↗1“Apatinib [Aitan® (brand name in China)], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine...” PMID 29663291 ↗ May 2018 |
| Known as | apatinib | “Drug sensitivity testing will be performed on a panel of approved targeted and immunotherapeutic agents (including Apatinib, Atezolizumab + Bevacizumab, Donafenib +...” NCT07363356 ↗536“The first-line targeted-immunotherapy regimens consisted of tislelizumab combined with one of the first-line evidence-based tyrosine kinase inhibitors (TKIs), including...” NCT07463248 ↗ “Treatment period: Therapeutic agents were selected according to clinical routine, including but not limited to Sorafenib, Lenvatinib, Donafenib, Regorafenib, Apatinib and Cabozantinib.” NCT05673824 ↗ “This phase II trial (NCT04318730) evaluated the efficacy and safety of the PD-1 inhibitor camrelizumab combined with the VEGFR inhibitor apatinib in previously treated advanced ACC.” PMID 39609453 ↗ Nov 2024 “administration regimen: Carillizumab 200mg, IV, D1; Albumin paclitaxel 150mg/m2, D1; Nedaplatin 50 mg/m2, D1; Apatinib 250mg Po D2-4.” NCT04666090 ↗ “Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on the 1st day 30minutes after meals, once a day, for continuous medication.” NCT05099848 ↗ “Apatinib: 250mg orally, QD, 5 days of medication, 2 days off (5 on 2 off) or once every other day (QOD), half an hour after meals” NCT06320301 ↗ “All participants will receive neoadjuvant therapy with combination of Camrelizumab、Apatinib and Temozolomide for 2 cycle；” NCT05512481 ↗ “Apatinib 250 mg twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days;” NCT05216237 ↗ “Apatinib mesylate tablets: The initial dose is 250 mg, administered once a day, and continue to be administered.” NCT04507750 ↗ “Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE Natural Killer /T-cell Lymphoma” NCT04366128 ↗ “Patients in the control group receive gemcitabine + oxaliplatin + apatinib as standard chemotherapy.” NCT07330271 ↗ “apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po” NCT03634059 ↗ “VRT106: Intravenous infusion Camrelizumab: Intravenous infusion Apatinib: Oral administration” NCT07589244 ↗ “E2: apatinib 250mg qd continuously combined with VP-16 50mg qd (three week on one week off)” NCT03805399 ↗ “Targeted therapy, with agents including but not limited to regorafenib and apatinib.” NCT07691645 ↗ “apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd” NCT04590625 ↗ “Apatinib :250mg,d1; which is taken continuously for 5 days and stopped for 2 days” NCT04723030 ↗ “atezolizumab+bevacizumab, camrelizumab+apatinib, sintilimab+bevacizumab and so on” NCT04135690 ↗ “Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy” NCT05367687 ↗ “oral Apatinib mesylate tablets (250 mg, once a day, for a total of 2 months)” NCT07154082 ↗ “Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma” NCT04588987 ↗ “Subjects receive Rivoceranib (Apatinib) orally, Dosage form: tablet” NCT04639180 ↗ “Apatinib: 250 mg orally once daily, with a 28-day treatment cycle.” NCT07000344 ↗ “Anti-Angiogenic Drugs contain endostatin, apatinib and anlotinib” NCT03461185 ↗ “Camrelizumab 200mg IV every 3 weeks; Apatinib 250mg QD day 1-14.” NCT04715633 ↗ “Mesylate Apatinib 500mg Po QD（once a day)） continuous use” NCT03154983 ↗ “Apatinib for oral administration, 250mg, once a day.” NCT04073784 ↗ “Apatinib oral administration, 500mg per day.” NCT03701022 ↗ “oral apatinib was started after discharge.” NCT06363825 ↗ “And apatinib will be administered orally.” NCT06666166 ↗ “Apatinib Mesylate Tablets：250mg，P.O，qod” NCT06614621 ↗ “Apatinib, 0.25g, once daily, orally” NCT07289997 ↗ “Subjects receive Apatinib orally.” NCT06739317 ↗ “Apatinib :250 mg or 375 mg, qd” NCT03912857 ↗ “Apatinib Mesylate 250mg po qd” NCT04203485 ↗ “apatinib, a VEGFR-2 inhibitor” PMID 40682106 ↗ Jul 2025 “Apatinib:425mg once daily” NCT03258034 ↗ “Apatinib 250 mg, po, qd” NCT05556200 ↗ “Rivoceranib (Apatinib)” NCT07105748 ↗ “apatinib 250 mg qd po” NCT06145308 ↗ “Apatinib 250 mg qd” NCT07333287 ↗ “Drug: apatinib” NCT01531777 ↗ “Apatinib” NCT04089657 ↗ |
| Known as | Apatinib (Apatinib Mesylate Tablets, Jiangsu Hengrui Medicine, China) | “Apatinib (Apatinib Mesylate Tablets, Jiangsu Hengrui Medicine, China)” NCT05742750 ↗ |
| Known as | Apatinib (registered name in China) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3186534 ↗ |
| Known as | Apatinib free base | ChEMBL registry synonym — accepted as the source's own label CHEMBL3186534 ↗ |
| Known as | Apatinib Mesylate | “Apatinib mesylate tablet is an oral small molecule tyrosine kinase inhibitor (TKI), which can specifically bind to vascular endothelial growth factor receptor 2 (VEGFR-2) and...” NCT04152681 ↗41“Apatinib mesylate: a small molecule of tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) , 250mg, once daily, to be swallowed with...” NCT06759090 ↗ “Apatinib Mesylate (Etan) is a new type of small molecule anti-angiogenic agent, which is a small molecule TKI against VEGFR2 independently developed in China and has the effect...” NCT05751733 ↗ “apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2...” NCT04397770 ↗ “Apatinib mesylate tablets: Orally, 500 mg, once a day, with warm water for half an hour after a meal (the time of taking the medicine every day should be the same as possible).” NCT04501705 ↗ “Apatinib mesylate: 250mg, qd, stopped 28 days before surgery, and can be used by the investigator according to the patient's recovery 28 days after surgery.” NCT04792515 ↗ “During the treatment period, 250 mg of Apatinib mesylate tablets will be taken orally daily continuously, and every 2 weeks is a treatment cycle.” NCT05342389 ↗ “Apatinib mesylate will be administered 250mg or 500mg (according to the patient's tolerance), qd, oral, until disease progression.” NCT04006821 ↗ “Apatinib mesylate is a new inhibitor of VEGFR-2 tyrosine kinase targeting the intracellular ATPbinding site of the receptor.” NCT03651219 ↗ “Apatinib mesylate is a small molecule VEGFR tyrosine kinase inhibitor authored by Jiangsu Hengrui Pharmaceutical Co., Ltd.” NCT03393507 ↗ “Continuous oral intake of Apatinib Mesylate (500mg), once a day, until progression of disease or severe adverse effect.” NCT03167385 ↗ “Apatinib mesylate 500mg, oral, once daily, adjusted according to patient tolerance, with a 4-week cycle;” NCT07236528 ↗ “Apatinib mesylate tablets (250 mg) will be administered orally in a 3-week treatment cycle, once a day.” NCT06480864 ↗ “Apatinib mesylate tablets treatment and to maintain the actual benefit in progression free survival.” NCT03255811 ↗ “Apatinib Mesylate Tablets 500 mg qd p.o. after the failure of chemotherapy or radiotherapy” NCT02683655 ↗ “Apatinib mesylate, 250 mg, administered orally once daily，once every 3 weeks.” NCT05320692 ↗ “Apatinib Mesylate is a small molecule VEGFR tyrosine kinase inhibitor.” NCT02976896 ↗ “apatinib mesylate: 250mg, once a day, taken orally” NCT06363825 ↗ “Apatinib Mesylate Tablets 250mg qd p.o. d1-35” NCT03857763 ↗ “Apatinib mesylate tablets: Oral, 250mg, qd.” NCT04501718 ↗ “Apatinib mesylate: 250 mg, p.o, qd” NCT04345783 ↗ “Apatinib Mesylate Tablets” NCT03048877 ↗ “Apatinib Mesylate Tablets” NCT07357532 ↗ “Drug: Apatinib Mesylate” NCT05235100 ↗ “Drug: Apatinib Mesylate” NCT05095636 ↗ “Drug: Apatinib mesylate” NCT05512481 ↗ “Drug: Apatinib Mesylate” NCT04126811 ↗ “Drug: Apatinib Mesylate” NCT05223088 ↗ “Drug: Apatinib Mesylate” NCT04260113 ↗ “Drug: Apatinib Mesylate” NCT05524974 ↗ “Drug: Apatinib Mesylate” NCT06539091 ↗ “Drug: Apatinib Mesylate” NCT04089657 ↗ |
| Known as | Apatinib mesylate tablets | “Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally 30minutes after meals, once a day, for continuous medication” NCT05313282 ↗6“Apatinib Mesylate Tablets 500 mg qd p.o.” NCT02509806 ↗ “Apatinib Mesylate Tablets：250mg，P.O，qod” NCT06614621 ↗ “Drug: Apatinib mesylate tablets” NCT03219593 ↗ “Drug: Apatinib Mesylate Tablets” NCT06188455 ↗ “Drug: Apatinib Mesylate Tablets” NCT02836821 ↗ “apatinib mesylate tablets” NCT03064243 ↗ |
| Known as | Apatinib Tablets | “Apatinib Tablets, recommended dose of 850mg” NCT02426034 ↗ |
| Known as | Etan | “Apatinib Mesylate (Etan) is a new type of small molecule anti-angiogenic agent, which is a small molecule TKI against VEGFR2 independently developed in China and has the effect...” NCT05751733 ↗ |
| Known as | mesylate apatinib | “mesylate apatinib, 250 mg, oral once a day, continuous oral” NCT04834674 ↗ |
| Known as | Methylsulfonic apatinib | “Methylsulfonic apatinib is one of those TKIs which specifically inhibits VEGFR-2.” NCT03491371 ↗ |
| Known as | rivoceranib mesylate | “Rivoceranib mesylate (750 mg, QD, po)” NCT04985136 ↗ |
| Known as | YN968D1 | “Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR).” NCT03390062 ↗3“BACKGROUND: YN968D1 (Apatinib) selectively inhibits phosphorylation of VEGFR-2 and tumor angiogenesis in mice model.” PMID 20923544 ↗ Oct 2010 “Apatinib(YN968D1) ,850mg,p.o.,qd,continuous.” NCT02493582 ↗ |
| Known as | YN968D1 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3186534 ↗ |
| Action | Inhibit | “YN968D1 (Apatinib) selectively inhibits phosphorylation of VEGFR-2 and tumor angiogenesis in mice model.” PMID 20923544 ↗ Oct 2010 |
| Modality | Small molecule | “It is an orally bioavailable, small molecule agent” NCT02515435 ↗ |
| Route | Oral | “orally administered apatinib” PMID 20923544 ↗ Oct 2010 |
| Target | RET | “Apatinib is an oral multi-kinase inhibitors including RET fusions.” NCT02540824 ↗ |